CASE REPORT article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Nanoparticle albumin-bound paclitaxel -induced severe interstitial lung disease in a gastric cancer patient: a Case Report
Provisionally accepted
- 1Weifang Traditional Chinese Hospital, Weifang, China
- 2Weifang People's Hospital, Weifang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background:Nanoparticle albumin-bound paclitaxel (Nabnab-PTX) is a novel formulation that combines paclitaxel with human serum albumin via nanotechnology. Without the need for solubilizers, it allows for higher safe doses, shorter infusion time, and no premedication for hypersensitivity prevention. Nabnab-PTX has been widely used in the treatment of various solid tumors. Its common adverse reactions include fatigue, alopecia, myelosuppression, etc., while pulmonary toxicity is extremely rare. To date, there are no reports of severe drug-induced interstitial lung disease (DILD) caused by Nabnab-PTX in gastric cancer patients. Case presentation:We report a case of a 77-year-old male patient with gastric adenocarcinoma. On the 15th day after receiving second-line Nabnab-PTX monotherapy, the patient developed chest tightness, dyspnea, high fever, and severe respiratory distress. High-resolution computed tomography (HRCT) of the chest showed diffuse exudative changes in both lungs, involving more than 90% of the lung fields. After excluding other causes such as pulmonary infection and tumor progression, the patient was diagnosed with severe Nabnab-PTX-related DILD. Nabnab-PTX was discontinued immediately, and the patient was treated with intravenous methylprednisolone sodium succinate. Subsequently, the pulmonary inflammation was gradually absorbed, and the clinical symptoms were significantly improved. Conclusion:Nabnab-PTX-induced severe interstitial pneumonia in gastric cancer patients is a rare and life-threatening adverse event. Clinicians should closely monitor respiratory symptoms and signs of patients receiving Nabnab-PTX, achieve early identification and timely intervention, so as to reduce the risk of adverse outcomes and improve patient prognosis.
Keywords: Adverse Drug Reaction, case report, Gastric adenocarcinoma, Interstitial Lung Disease, Nabnab-PTX
Received: 21 Jan 2026; Accepted: 13 Feb 2026.
Copyright: © 2026 Liu, Wei, Dong and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiuli Zhou
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.